The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Interfering with Interferon: Experts Discuss IFN Signaling & IFN Inhibition Treatment Possibilities

Interfering with Interferon: Experts Discuss IFN Signaling & IFN Inhibition Treatment Possibilities

January 25, 2021 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence graphicACR Convergence 2020—The types of autoinflammatory and rheumatic diseases that may be effectively treated by blocking type 1 interferon (IFN) are growing as more is understood about IFN signaling as a pathomechanism amplifying immune dysregulation in a range of clinical diseases.1–3 In a session titled Interfering with Interferon, investigators from the U.S. National Institutes of Health (NIH) described key features and genetic causes of Mendelian interferonopathies and treatment approaches that may indicate the efficacy of IFN inhibition, such as with Janus kinase inhibitors (JAKinibs).

You Might Also Like
  • Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA
  • Osteoporosis Experts Discuss Bisphosphonate Holidays
  • MRI & Axial Spondyloarthritis: Experts Discuss Controversies in the Diagnostic Evaluation of axSpA
Explore This Issue
February 2021
Also By This Author
  • Study Suggests Tocilizumab Monotherapy May Work for Some RA Patients

Dr. Goldbach-Mansky

Raphaela Goldbach-Mansky, MD, MHS, a senior investigator in the Translational Autoinflammatory Diseases Section in the National Institute of Allergy and Infectious Diseases (NIAID), spoke on a group of model diseases that illustrate the spectrum of clinical features associated with a chronically elevated IFN signature.4 Falling under the general category of autoinflammatory Mendelian interferonopathies, these include SAVI (STING-associated vasculopathy with onset in infancy), CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures) and AGS (Aicardi-Goutières syndrome).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

She discussed a set of clinical features of these diseases that may indicate type 1 IFN as a potential pathomechanism, including neutrophilic rashes (particularly neutrophilic panniculitis), lipodystrophy, vasculopathies (e.g., chilblain lesions), interstitial lung disease, primary pulmonary hypertension, myositis, neurological findings (e.g., encephalopathy) and imaging findings (e.g., basal ganglia calcifications or leukoencephalopathy).

“Such findings in patients with inflammatory diseases even in the absence of disease-causing mutations should prompt the investigation for an interferon-mediated disease process,” said Dr. Goldbach-Mansky. “Unfortunately, tests that probe for an IFN signature are not yet clinically available but would significantly enhance our diagnostic armamentarium.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Goldbach-Mansky also described conditions that can mimic these diseases and that also show IFN dysregulation, such as spondyloenchondrodysplasia, deficiency of adenosine deaminase 2 for SAVI or trichohepatoenteric syndrome for AGS. Other conditions (e.g., NEMO-exon 5 deletion autoinflammatory syndrome, which mimics CANDLE) are novel diseases that have a more complex inflammatory signature that includes IFN signaling. “Knowing the genetic mutations will help in further studying pathways and finding targets for treatment of more complex diseases,” she said.

‘Unfortunately, tests that probe for an IFN signature are not yet clinically available.’ —Dr. Goldbach-Mansky

She underscored the promise of these findings for improving treatment. “With the increasing number of agents that target IFN signaling, including JAK inhibitors, antibodies to the IFN receptor and [future] STING inhibitors, there is light at the end of the tunnel with better treatment options on the horizon not only for patients with rare autoinflammatory diseases, but also for patients with complex diseases caused by IFN dysregulation,” she said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2020, interferon, JAK inhibitors, jakinib, signalingIssue: February 2021

You Might Also Like:
  • Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA
  • Osteoporosis Experts Discuss Bisphosphonate Holidays
  • MRI & Axial Spondyloarthritis: Experts Discuss Controversies in the Diagnostic Evaluation of axSpA
  • COVID-19, New Research & More: 2 Experts Discuss Scientific Advances in Rheumatology at ACR Convergence 2020

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.